Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Annals of the Rheumatic Diseases
Cem GabayEduardo Jorge Schiffrin

Abstract

Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study. Ten patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three seriou...Continue Reading

References

Sep 5, 2006·Seminars in Arthritis and Rheumatism·Petros Efthimiou, Sharon Georgy
Jul 14, 2012·International Journal of Inflammation·Clio P MavraganiMichael Koutsilieris
Dec 21, 2012·The New England Journal of Medicine·Fabrizio De BenedettiUNKNOWN PRCSG
Dec 21, 2012·The New England Journal of Medicine·Nicolino RupertoUNKNOWN PRCSG
Oct 12, 2013·Frontiers in Immunology·Charles A DinarelloGilles Kaplanski
Mar 25, 2014·Autoimmunity Reviews·Mathieu Gerfaud-ValentinPascal Sève
May 3, 2014·The Journal of Rheumatology·Roberta PrioriGuido Valesini
Sep 13, 2016·Rheumatology·Charlotte GirardCem Gabay
Nov 26, 2016·Best Practice & Research. Clinical Rheumatology·Santos CastañedaMiguel A González-Gay
Feb 16, 2017·Joint, Bone, Spine : Revue Du Rhumatisme·Stéphane MitrovicBruno Fautrel
Dec 29, 2017·Curēus·Wahinuddin SulaimanNorain Karim

❮ Previous
Next ❯

Citations

Apr 18, 2019·Scientific Reports·Naotaka TsutsumiHidehito Tochio
May 31, 2019·Clinical Reviews in Allergy & Immunology·Sheng LiJianjun Qiao
Sep 17, 2019·Arthritis & Rheumatology·Sarah Nikiforow, Nancy Berliner
Oct 26, 2018·Annals of the Rheumatic Diseases·Uta KiltzCem Gabay
Jun 30, 2019·European Journal of Immunology·Yasmina E Hernandez-SantanaPatrick T Walsh
Jun 4, 2018·Annals of the Rheumatic Diseases·Philippe GuilpainAlexandre Thibault Jacques Maria
Aug 15, 2020·Journal of Cellular Physiology·Alessandra VecchiéAntonio Abbate
Apr 17, 2018·Expert Review of Clinical Immunology·Stéphane Mitrovic, Bruno Fautrel
Feb 14, 2019·Arthritis Research & Therapy·François VercruysseMarie-Elise Truchetet
Oct 21, 2020·Expert Opinion on Drug Safety·Giulio CavalliLorenzo Dagna
Mar 7, 2021·Journal of Clinical Medicine·Stylianos TomarasEugen Feist
Mar 13, 2021·Frontiers in Pharmacology·Hana MalcovaRudolf Horvath
Mar 19, 2021·Frontiers in Medicine·Yasuaki Hirooka, Yuji Nozaki
Aug 25, 2021·Pediatric Rheumatology Online Journal·Lina N ZaripovaRachel A Oldershaw
Apr 10, 2018·Joint, Bone, Spine : Revue Du Rhumatisme·Charlotte Girard-Guyonvarc'h, Cem Gabay

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02398435

Related Concepts

Related Feeds

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain, and a distinctive salmon-colored bumpy rash. Discover the latest research on AOSD here.